Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
about
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyIncreased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.Treatment options for myelodysplastic syndromes.The role of lenalidomide in the management of myelodysplasia with del 5q.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.Recent advances in the treatment of acute myeloid leukemia.Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemiaSWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Current therapeutic strategies for acute myeloid leukaemia.Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Myelodysplastic syndromes: clinical practice guidelines in oncology.Upfront therapy of acute myeloid leukemia.Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?The evolving landscape in the therapy of acute myeloid leukemia.Deacetylase inhibitors for the treatment of myelodysplastic syndromes.Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.Update on optimal management of acute myeloid leukemiaClinical activity of laromustine (Onrigin™) in hematologic malignancies.Troxacitabine activity in extramedullary myeloid leukemia.Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?Long-term remission of APL with a second allogeneic BMT after CNS relapse following HLA-identical allogeneic BMT.Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance.Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P2860
Q24563021-54C3416B-3491-47FB-9471-48FC426ED6DBQ33357735-F3B764D0-4743-40B4-8E2A-BB5AB63C2F2AQ33364350-7C941CA0-6E4C-4F12-8B68-A2CA9520A5F3Q33378398-04335952-C46B-4D8E-9C20-BA2AF0287FC2Q33393647-4619E614-6BE1-452B-87F7-E2E5FF48009BQ33968372-B38DE513-EC97-4546-A1A8-8B240BA89769Q34018590-017577F6-8AA7-428D-9F50-C50AA31D9BFCQ34082437-51E021F8-F39B-425F-B1CF-22D71A7B2CF8Q34279037-93D35A5F-109D-47D5-B216-72CEEB726C5CQ34302258-9FA40C71-2289-431E-85CA-BB2F728E2E43Q35001132-EA9E7162-0AF7-4C89-8F8A-126DEF25F3EDQ35034815-8BE6F8F4-6F73-4FF1-8011-E80876F688BAQ35134989-4F1C978A-0D72-4B39-8013-E83101D0B201Q35584427-6CD4AE66-7551-4FFE-A66D-0290281EF5B9Q35750986-DBAB7488-05AD-4FF4-A052-68000FEDB1DDQ35847836-D560D688-1767-4379-9971-01345B49B7ACQ35980938-60901484-F66F-4B8D-8CDB-E71F17052284Q36539598-31176508-F78A-41A6-A194-6A3390CEE037Q36716744-DC9C84C4-1DA4-42C7-8DBD-FEDCE88EB13DQ37323006-0A7C4086-1187-4562-A806-299FE506066FQ37723847-638494FD-7DE1-4CE8-A6D1-8FBEEE0ED503Q37897183-BA352505-6245-4133-A4EC-076664E3C9C0Q37978341-ED675114-A262-4B03-8B53-56ABBDE39CDDQ38132064-30B04492-CB4D-4602-8C0E-6D2F3A93468BQ38233492-41A431D6-3C1F-4CC8-B924-FB425432A5D6Q40528087-A9B16AF5-92E4-4CDA-BC22-ECD1D633604CQ41894404-7A1B2801-E3A0-4ADB-9B18-6AB1784C13BBQ42807419-79DEA26B-7AC9-4A79-9024-49FEE4BE3347Q44146994-09D0C528-28D2-46BD-BC2E-8A996B87F68DQ44785640-19F0F361-AE74-40B0-8860-A0C5D851FAC0Q48229854-2EA9F771-418B-432A-B251-8BD006341919Q53916207-864B7004-0303-4DA6-9625-F4494D4443C0Q54596100-54416129-718B-4E36-BC5D-9AF4CED7812CQ55969986-8FB7029A-1579-4074-9288-E3CF9569F1CF
P2860
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Comparison of idarubicin + ara ...... ory anemia with excess blasts.
@en
Comparison of idarubicin + ara ...... ory anemia with excess blasts.
@nl
type
label
Comparison of idarubicin + ara ...... ory anemia with excess blasts.
@en
Comparison of idarubicin + ara ...... ory anemia with excess blasts.
@nl
prefLabel
Comparison of idarubicin + ara ...... ory anemia with excess blasts.
@en
Comparison of idarubicin + ara ...... ory anemia with excess blasts.
@nl
P2093
P1433
P1476
Comparison of idarubicin + ara ...... ory anemia with excess blasts.
@en
P2093
Kantarjian HM
P304
P356
10.1182/BLOOD.V98.13.3575
P407
P577
2001-12-01T00:00:00Z